GC Biopharma’s FDA Approval for ALYGLO Signals US Market Entry

GC Biopharma has officially entered the United States, the world's largest pharmaceutical market, leveraging its expertise in blood product manufacturing. Eun Chul Huh, CEO of GC Biopharma, announced on December 18th the FDA approval for 'ALYGLO,' a 10% immunoglobulin preparation for intravenous administration used in Primary Humoral Immunodeficiency (congenital immunodeficiency).

In 2020, GC Biopharma conducted Phase 3 clinical trials in North America targeting primary immunodeficiency patients, meeting FDA guidelines for efficacy and safety evaluations. Despite a delayed Pre-License Inspection in April due to the COVID-19 pandemic at their Ochang, Chungbuk facility, the company resubmitted their Biologics License Application (BLA) for biological products on July 14th.

Ahead of the previously communicated January 13th deadline under the Prescription Drug User Fee Act (PDUFA) by the FDA, the company received approval, intending to launch ALYGLO in the U.S. market through its subsidiary, GC Biopharma USA, in the second half of the upcoming year.

This milestone marks the first entry of South Korean blood products into the U.S. market, highlighting the challenge in producing these products globally, often leading to shortages due to high demand and significant facility investments required.

GC Biopharma ensured product safety by integrating their proprietary 'CEX Chromatography' technology into the immunoglobulin purification process. This technology effectively removes impurities, such as coagulation factor XIa, significantly enhancing the product's safety. Details of this innovation were recently published in the international journal 'Frontiers in Cardiovascular Medicine.'

Eun Chul Huh expressed enthusiasm for offering a safe and effective treatment option for immunodeficiency patients in the United States, emphasizing the company's dedication to improving treatment environments for patients and healthcare professionals worldwide.

Meanwhile, the U.S. immunoglobulin market, estimated at $10.4 billion based on 2022 MRB data, continues to grow steadily due to an aging population driving an increase in autoimmune diseases, furthering the demand for immunoglobulins in the country.